Abstract
No public abstract is available from the verified source records.
Shenglan Yang, Jianpei Wen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Targeting the NLRP3 inflammasome in cardiovascular diseases
10.1016/j.pharmthera.2021.108053 · 2022
Combined effects of biomarkers in the NLRP3 inflammasome axis and cardiovascular outcomes in multi-vessel disease
10.1016/j.jacasi.2026.06.040 · 2026
The NLRP3 inflammasome in kidney disease and autoimmunity
10.1111/nep.12785 · 2016
NLRP3 inflammasomes: dual function in infectious diseases
10.4049/jimmunol.2300745 · 2024
Antiinflammatory therapy with canakinumab for atherosclerotic disease
10.1056/nejmoa1707914 · 2017
Efficacy and safety of low-dose colchicine after myocardial infarction
10.1056/nejmoa1912388 · 2019
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
10.1093/eurheartj/ehz542 · 2020
No additional external references are available.